ABSTRACT-The development and evaluation of experimental designs for routine In vivo screening of chemicals for potential carcinogenic activity were considered. Such designs have played an Important role In the Carcinogenesis Bioassay Program of the National Cancer Institute (NCI). In particular, the current onestage 50-animal/group screen used by the NCI was considered. A specific two-stage alternative was proposed In which 35 anlmals/ group were used; this alternative allowed for retesting of equivocal compounds. The proposed designs were evaluated In terms of sensitivity, specificity, and throughput. Despite the large number of tests made for each compound, the false-positive rate was found to be less than 0.07 for the current screen and less than 0.05 for the proposed two-stage alternative. Several Government and industrial agencies have set up carcinogenesis testing programs to identify those chemicals in our environment with carcinogenic potential and then to provide information for use in regulatory actions. In general, these programs use onetime-only, long-term animal experiments to study chemicals when evidence for regulatory purposes is desired. Compounds are defined as carcinogens if treated animals have significantly more tumors at some site(s) than do untreated controls. Detailed results of the experiments provide guidance concerning the appropriate regulatory actions. Such experiments are costly, however-not just in money, but also in the time that highly skilled scientists must devote to the conduct and analysis of the study. In this paper, we compare a one-stage animal testing program with a program based on two-stage animal tests. The initial test in the two-stage program would be made with smaller groups of animals than in a one-stage program and equivocal compounds would be retested. The advantages of such a two-stage design are considered.
Several Government and industrial agencies have set up carcinogenesis testing programs to identify those chemicals in our environment with carcinogenic potential and then to provide information for use in regulatory actions. In general, these programs use onetime-only, long-term animal experiments to study chemicals when evidence for regulatory purposes is desired. Compounds are defined as carcinogens if treated animals have significantly more tumors at some site(s) than do untreated controls. Detailed results of the experiments provide guidance concerning the appropriate regulatory actions. Such experiments are costly, however-not just in money, but also in the time that highly skilled scientists must devote to the conduct and analysis of the study. In this paper, we compare a one-stage animal testing program with a program based on two-stage animal tests. The initial test in the two-stage program would be made with smaller groups of animals than in a one-stage program and equivocal compounds would be retested. The advantages of such a two-stage design are considered.
To evaluate designs for the animal experiments used in carcinogenicity testing programs, one must specify basic objectives and requirements. One objective of a carcinogenicity testing program is to test completely as many materials as possible as quickly as possible subject to control of various error rates. The number of compounds completely evaluated per test period is important. Delay in testing a chemical is a source of possible hazard, inasmuch as untested materials are often treated as having no risk.
The design of a carcinogenesis testing program calls for a balancing of several apparently conflicting requirements. First, the test procedure should have good sensitivity. Declaring a hazardous (positive) material to be safe (negative) is a serious error. We would like to have no false negatives, but a decision rule that could accomplish this would have to declare positive many noncarcinogenic compounds. Thus we ask that a program have a low false-negative rate. Next, the program must have good specificity. A substantial loss to society may occur if a useful negative (safe) compound is declared positive (a carcinogen). We would prefer no false positives, but we must settle for a low false-positive rate in any realistic test procedure.
One-stage carcinogenicity screens are well established. We will, therefore, assume an existing program in which all questions of balancing error rates or the size of the screen have been tacitly resolved, even approximately. The false-positive rates, false-negative rates, and size of the current program then constitute the operating characteristics required of any new replacement program. We assume that testing procedures will continue much as they are now and ask if twostage testing will allow more compounds to be tested per unit time without altering the error rates. In the next section we outline the existing (one-stage) program and a possible two-stage alternative to this program. We then discuss in a subsequent section the design and methods of analysis of the present NCI experimental protocol and give particular attention to error rates, because these rates provide standards of comparison for alternative designs. In a separate sec-ABBREVIATIONS USED: MTD= maximum tolerated dose; NCI= National Cancer Institute.
TEXT-FIGURE I.-Schematic diagram of one-stage carcinogenicity screen.
untreated group would contain 35 rather than 50 animals. When the results of the first chronic study are reported, compounds would be identified as positive, equivocal, or negative. For purposes of the screening program, clearly positive and clearly negative compounds would not be examined further. Compounds considered equivocal would undergo a second confirmatory study with the use of essentially the same experimental protocol. Thus at stage 1, compounds would be called positive on the basis of strong evidence of increased tumor incidence at one or more sites.
Compounds would be called negative at stage 1 only if no evidence existed of increased tumor incidence at any site. All other compounds are classified as being equivocal upon completion of the stage-I screen and a stage-2 screen is undertaken. In the stage-2 screen, a single control group and a single treated group would be used for each of the 4 sex-species groups. Each control and treated group again would have 35 animals. Only those target sites identified in the first chronic study would require microscopic examination. The dose given would be the stage-l MTD if it were not toxic, or one-half the stage-l MTD if the MTD had proved to be toxic. Thus the two-stage alternative to the NCI protocol involves dose determination; the first chronic studies; histopathology, data analysis, and recommendations; the. second chronic study (if needed); reduced histopathology, data analysis, and recommendations on the chronic studies (text- fig. 2 ).
Clearly, in a two-stage screen, if a compound goes through both stages, the testing process will take longer than in a one-stage screen. For the types of compounds studied here, we find that most compounds will be tested only once, and on the average fewer 
Existing Program and a Two-Stage Alternative
tion, the two-stage screen presented in an earlier section is considered in more detail, and the error rates for this screen are compared with those found for the present NCI design. In a final section we discuss the testing rate of the proposed two-stage protocol, i.e., how many decisions are made per test period.
The modifications considered in this paper involve little change in existing programs. We do not at this time consider the role of quick screens such as mutagenicity tests; tissue culture tests; short-term, sitespecific animal tests; long-term animal studies designed to discover dose-response effects; serially killing animals during the course of the experiment; and other designs suggested by many statisticians and experimental pathologists. One of our major goals in this paper is to describe an approach to comparing designs.
The routine screening program for carcinogens as conducted by the Carcinogenesis Program of the Division of Cancer Cause and Prevention of the NCI (1) will be used to define the desired operating characteristics or requirements for a proposed program based on two-stage screening designs. We describe certain essential features of this design that we require for our comparative studies. The current one-stage design has an initial dose determination experiment lasting for 6 months. This phase is followed by a chronic study during which the compound under test is administered continuously (usually by feeding) for 18-24 months to male and female rats and mice. For each of the four sex-species combinations, there are 2 treated groups with 50 animals each and an untreated control group with 50 animals. The animals in the group treated with the high dose are given the test compound at the MTD and the animals in the group treated with the low dose are given the chemical at one-half the MTD. The MTD has been defined (1) as the highest dose that leads to a weight loss of 10% or less when given in a subchronic study and which does not produce mortality, clinical signs of toxicity, or life-shortening pathologic lesions other than those related to a neoplastic response. For each animal in the experiment, the data are the age at death and the presence or absence of primary tumors at those organ sites examined at necropsy. Throughout this paper, no attempt was made to use information on mortality times.
For our purposes, the present animal carcinogenicity test has three main aspects: dose determinations; the chronic experiments; and histopathology, data analysis, and recommendations (see text- fig. 1 ). In practice the current screen contains an informal two-stage mechanism because chemicals believed to be "equivocal" upon completion of testing are considered for a possible retest.
In the alternative two-stage design that we propose, a dose determination study is followed by the first chronic study. The first-stage experiments would be the same in all ways as the present design described in text-figure I except that each treated group and each situations in this paper. Consider a given site in a single sex-species group (l of 4 such groups). The chronic experiment produces site-specific tumor incidence rates for the control group and each treated group. With the use of the one-sided Fisher-Irwin exact test at a specified nominal significance level P (usually,~0.05), the site-specific rates for a treated group and the appropriate control group can be compared. These comparisons are performed for each site in each sex-species group. For sites believed before the experiment to have spontaneous tumor incidence rates greater than 2%, we classify a chemical as a carcinogen (or positive) at a given site if a significant (P~0.05) tumor increase is observed in both treatment groups for at least one sex-species group. For the remaining sites, those with spontaneous tumor incidence rates less than 2%, we will classify a compound as a carcinogen if a significant tumor increase is observed at either dose for any sex-species group. A compound not classified as a carcinogen is regarded as a noncarcinogen (or negative) for our purposes. These decision rules will be referred to as "method I decision rules."
Other decision rules are possible. Recently, it has been suggested (2) that a compound be classified as carcinogenic if the comparison of either treated group with the appropriate control group is significant. We considered a version of this decision rule in which treatment-control group comparisons are made with the use of the Fisher-Irwin exact test with nominal significance level P= 0.05 for sites with spontaneous rates less than 2%. A nominal significance level of P= 0.025 is used for the remaining sites. These decision rules will be referred to as "method II decision rules," and they were suggested in discussions with the NCI statistical group led by Dr. John Gart. This group has formulated the statistical analysis protocol for the Applied Bioassay Group at NCI.
For sites with high spontaneous incidence rates, i.e., greater than 2%, a decision rule requiring biologic consistency provides protection against false positives with little loss in the ability to detect a carcinogen (called "the power of the test"). The use of less stringent decision rules for low-incidence sites will lead to an increase in power, whereas the false-positive rate remains small. Low-incidence sites might also be handled by means of the NCI data base on control animals. If different decision rules are to be used for various site comparisons, the choice of which rule to use for each site must be made prior to the experiment and not after the data have been observed. Classification of a site with a low spontaneous rate as having a high spontaneous rate increases the false-negative rate of the screen, whereas classification of a site with a high spontaneous rate as having a low rate increases the false-positive rate.
The NCI has data available on tumor incidence rates in control animals at 20 sites for (C57BL/6 X C3H)F, (B6C3Fl) mice and F344 rats for each sex. Estimates of these rates are given in (3) animals will be used per compound tested than are currently being used. The savings can be used to test more compounds by increasing the number of chemicals tested per test period. Also, as will be shown, a large pool of chemicals can be tested in a much shorter time by means of the two-stage design rather than the one-stage design.
The evaluation of the carcinogenic properties of a test compound is a complex process. Any decision made about the carcinogenic activity of a chemical must be based on the combined knowledge of all participants-the chemist, the pathologist, the statistician, and the toxicologist. To define a single set of decision rules that would apply in all situations has not been possible. With this strong note of caution in mind, we proceed to outline a simple decision strategy.
We assume that the data analyses for the chronic studies can be based sensibly on the site-specific tumor (malignant or benign) incidence rates rather than survival times. Situations can arise in which, due to non-tumor toxicity or other reasons, other methods of analysis are appropriate. We do not consider such tests at the nominal significance level of p= 0.05, the overall false-positive rates for each site are under 0.05, with the largest being 0.016 for pituitary tumors. Table  3 presents false-positive rates based on the method II decision rules. The false-positive rates are increased dramatically at sites having spontaneous rates greater than 2%. The overall false-positive rate for this screen with the use of the method II decision rules is 0.234.
The ability of a screen to detect a carcinogen is difficult to specify, inasmuch as the power depends on both the spontaneous tumor incidence and the tumor incidence rate in the treated animals. Any chemical associated with any increase in tumor rates, no matter how small the increase, is of concern. Because we cannot specify the power of a screen for all possible increases, we consider several possibilities. Table 4 presents the power at selected sites of the NCI screen defined in text-figure 1. The computations were made by means of the method I decision rules and the spontaneous rates given in table 1. It was assumed that the tumor incidence rate for each treated group was increased by an amount~. Increases of 0.04, 0.06, 0.08, and 0.10 are considered. For example, from table I we see that the spontaneous tumor incidence rate for the 4 sex-species groups for lung-trachea tumors are 0.092, 0.035, 0.024, and 0.010. The power of the screen to detect an additive increase of 0.04 was found on the assumption that the tumor incidence rates for each treated group are 0.132, 0.075, 0.064, and 0.050. From table 4 , we see that in this case the experiment described here will detect this increase only 18% of the time. The values given are lower bounds inasmuch as they do not incorporate the probability of a false-posi- Mouse, B6C3Fl a Site false-positive rates in experiments in which many sites are examined. For convenience, table 1 presents these estimated spontaneous tumor incidence rates. Rates for testicular tumors are omitted from this table because male F344 rats have such a large spontaneous rate at this site (0.76) that testicular tumors are usually excluded from analysis. In some cases, one may be interested in specific tissue types within a given site or sites. In these cases, each tissue type can be considered analogously to a site in the evaluations presented in the sequel. False-positive rates were computed for the design of text- figure 1 and the NCI data on spontaneous rates. These computations were performed with both sets of decision rules already described. Table 2 summarizes the site-specific false-positive rates for each sex-species group with the use of the method I decision rules. In addition, table 2 presents the sitespecific false-positive rate bounds for the whole fourexperiment screen as well as overall false-positive rate bounds for each sex-species group and for the full screen. These overall rates have little, if any, biologic meaning in the consideration of a specific compound; however, these quantities do provide important and meaningful information about the performance of a screen.
With the use of the method I decision rules, the overall false-positive rate bound is 0. One can also consider the effect of other patterns of activity upon the performance of the screen. In particular, one might be interested in compounds that affect only one species, e.g., rats. Although we can perform such computations, we do not report these results here to avoid the further lengthening of the manuscript. In addition, the primary purpose of this work has been the development of general methods for the evaluation and comparison of various screens. Further detailed comparisons of specific designs have been performed. tive result for a nonactive site when a false-negative error is made at the correct site, i.e., the probability of the correct identification of a compound as a carcinogen for the wrong reason.
Decision Rules and Requirements in a Two-Stage Design
Examining these tables, we see that the current screen performs reasonably well at most sites in detecting compounds that lead to increases of 0.08 or more for each treated group. For smaller increases, the screen tends to lack power at all sites. Table 5 presents similar power computations based on the method II decision rules. For sites at which the spontaneous rate is less than 2%, the power is the same as was found with the use of the method I decision rules. For other sites, such as lung-trachea, at which the spontaneous rate is greater than 2% in one or more sex-species groups, the power is considerably increased. For example, a compound leading to an increase of 0.04 over the spontaneous rate in each sex-species group for lung-trachea tumors will be detected 37% of the time. This increase in power by means of the method II decision rules is accompanied by an increase in the false-positive rate of method II over method I. Dependent on one's point of view toward inference, the increase in false-positive rate can be substantial as indicated in our preceding dis- CUSSIon. Evidence exists that in some instances a carcinogenic compound will not affect each sex-species group in the same manner. Table 6 presents the power of the screen, with the use of the method I decision rules, to detect compounds that affect only females. That is, tumor incidence for treated females is increased by the amount indicated, whereas tumor incidence rates for males are formally implemented by the Bioassay Program, although such designs are used, e.g., to screen substances for antitumor activity (4) . To demonstrate the performance of such a design, we require a strategy to indicate when and how to classify a compound. Several approaches were explored (5, 6) to develop a satisfactory strategy. We will outline one approach that has proved promising.
The decision rules for a two-stage screen involve additional considerations. At stage 1, a chemical is classified as either positive, negative, or equivocal. Following stage 2, if one is needed, the compound will usually be classified as either positive or negative. Thus to specify a set of decision rules, we must specify when a compound is to be called positive and when a compound is to be called equivocal. For some compounds tested it is necessary to repeat the screen due to experiments that cannot be evaluated. The data from such screens cannot be used in making a decision due to poor choice of dose schedules, mishandling of animals, or numerous other problems. On these occa-sions when a (stage 1 or stage 2) screen cannot be evaluated, it is necessary to repeat the screen. Of course, such an experiment is more costly for a onestage than for a two-stage design.
One set of decision rules for a two-stage screen is presented. We first develop criteria for the classification of a compound as positive and then present decision rules that determine which compounds are negative and which are equivocal.
Proposed Decision Rules: Positive Classification
Stage 1.-The strategy criteria for a positive result in stage 1 are analogous to those of a one-stage design. At stage 1, the tumor incidence for each site in each treated group is compared to that in the appropriate control group. This comparison is made by means of the Fisher-Irwin exact test with a nominal significance level of 0.05. For sites believed to have a spontaneous tumor incidence greater than 2%, it is required that significant increases. be observed at both dose levels for one or more sex-species groups at a site for the compound to be classified as a carcinogen (or positive). For the remaining sites, a compound is classified as a carcinogen (or positive) if any of the comparisons for a sex-species group is significant at a site.
Stage 2.-Any compound tested in the second stage has already produced an equivocal result at stage 1. Some reason already exists to suspect the compound, and we are looking for confirmatory results. Therefore we test at a nominal significance level of 0.20 at stage 2 for sites having a spontaneous rate less than 2% and a significance level of 0.05 for the remaining sites. At stage 2 of our design there is a single control group and a single treatment group for each sex-species group. Thus the decision at stage 2 must be based on one comparison for each sex-species group at each site. Each treatment group is compared to the appropriate control group with the use of the Fisher-Irwin exact test. A chemical is declared positive if there is a significant increase in tumor incidence at any site for any of the sex-species groups.
The decision at stage 2 does not explicitly make use of the stage-l data. After the decision to continue, i.e., to look for confirmatory results, has been made, the stage-l data is not used further. Various methods for combining stage-I and stage-2 data have been considered (6) . For the type of design considered here, we found that the gain from combining stage-I and stage-2 data in an appropriate manner is negligible. This implies that, in instances in which a second stage is required, the final decision effectively uses all the information in the data (i.e., from both stages).
Proposed Decision Rules: Equivocal Classification
How do we proceed with a compound not classified as a carcinogen at stage 1? First, let us consider the comparisons in a single sex-species assay-the comparisons of the control with each of 2 treated groups at each site. For a site with a spontaneous tumor incidence rate greater than 0.02, an equivocal result is obtained when one comparison is significant (P<0.05) and the other is suspicious. For sites where the spontaneous tumor incidence rate is less than or equal to 0.02, an equivocal result is obtained if either comparison has a suspicious increase and neither comparison is significant. A second stage is undertaken for any compound having an equivocal result at no less than one site and no positive results.
What is a suspicious comparison? This question was studied in (6) for a simple one-treatment, one-site, twostage design. The approach in (6) is formulated here for multisite designs as follows: Sites are called low-, moderate-, or high-tumor-incidence sites if the sitespecific spontaneous incidence rates are less than or equal to 5%, between 5% and 15%, and greater than or equal to 15%, respectively. A suspicious region is 
specified for each of these three types of sites; e.g., the suspicious region for low-tumor-incidence sites is displayed in text- figure 3 . The upper boundary for the region is the same for all three groups. The lower boundary is raised for spontaneous rates in the middle group and raised further for spontaneous rates in the high group. In a two-stage screen, compounds can be classified as positive at either the first or the second stage. An equivocal result can be obtained only at the first stage. If a compound is neither positive nor equivocal at stage I, it is called negative. If a compound is equivocal at stage 1 and not positive at stage 2, it is called negative. The decision rules for a site at stage 1 of the proposed screen are summarized in table 7.
Although not considered in this presentation, a twostage screening program may lead to a situation in which a compound is still regarded as equivocal at the end of the second stage. In such a situation, further testing or review may be necessary.
Proposed Decision Rules: Requirements
In discussing error rates for this two-stage screen, we present overall summaries. The pattern of site-specific error rates by sex-species group is similar to that presented in detail for the one-stage screen. Using the two-stage design just specified, together wi th these decision rules and the tumor incidence rates for controls presented in table I, we find that the overall falsepositive rate is less than 0.05, and the probability that a noncarcinogen requires a second stage screen is less than 0.04. In table 8, the site-specific false-positive rates are given for each of the 20 sites considered. This table presents, for each site, the overall false-positive rate, (x, as well as the stage-I and stage-2 conditional false-positive rates, (Xl and (X2, respectively, and the continuation probability for noncarcinogens, ) 1 at the 0.20 significance level. For sites at which all stage-2 comparisons are made at the higher nominal significance level, the largest stage-2 false-positive rate, 0.016, occurs for stomach tumors. On the basis of table 7, it does not appear that the use of a nominal significance level of 0.20 for some sites in some sex-species groups leads to unreasonable false-positive rates for this design. The power of this two-stage screen to detect chemicals that are active at only one site and that affect each treated group is given in table 9. The alternatives considered are identical to those used for the one-stage screen. Comparing the power for this two-stage screen with that for the current one-stage screen (table 5) , we see that although the two-stage screen has less power, the loss in power is most marked for small increases in the tumor incidence rate «0.06). However, in these cases each screen has low power. For larger increases, both screens perform quite well at most sites. Table 10 presents the power of this two-stage screen to detect compounds that affect tumor incidence rates for female rats and mice only. As was the case for the TABLE 
9.-Lower bounds on the power of the two-species, two-stage, 35-animallgroup design for various increases in tumor probability
one-stage screen, there is a decrease in the power of the screen in the face of reduced activity. For both the standard one-stage protocol and the two-stage protocol presented here, each tissue had to be classified for each sex-species group on the basis of the spontaneous tumor incidence rate. This classification must be performed prior to the analysis of the data. It was assumed throughout the examples discussed in these two sections that these classifications were made correctly. To assume that the investigator possesses perfect prior information is not reasonable. Investigation of the potential effect of classification errors indicates that if all the spontaneous rates for a site are small (~0.02) and each site is classified as having rates greater than 0.02, there is a marked loss of power for both the one-stage and two-stage screens. If, however, for some sex-species group the spontaneous rates are greater than 0.02, the loss of power is less. Errors in which sites having a true spontaneous rate greater than 0.02 are classified as having a rate less than 0.02 have little effect on either sensitivity or specificity. This is due to the fact that most tissues in the animals used have spontaneous rates less than 0.02 and hence are unaffected by errors of this type.
OBJECTIVES OF A PROGRAM
In the previous two sections, we have shown that it is possible to develop a two-stage screening procedure that achieves approximately the same error rates, both false-positive and false-negative, as the current onestage design. We will now show that these designs use fewer animals on the average than a one-stage design. Thus a two-stage screen can lead to savings in sample size and hence will permit more chemicals to be tested during each test period.
The number of animals required to reach a decision on a compound with the use of a two-stage screen varies. For example, a truly negative compound is likely to require only the first-stage test (i.e., 420 animals); however, if we got an equivocal result at stage 1 leading to a second-stage test, we would use a total of 700 animals for the experiment. The expected (or average) number of animals needed to test a negative compound is therefore 0.96(420)+0.04(700) = 431 animals. The present one-stage test always requires 600 animals to test a compound. Thus this two-stage screen Table 11 gives the expected number of animals required to test carcinogens of various strengths. This table is based on the spontaneous tumor rates of the B6C3Fl mouse and the F344 rat, the design and decision rules for the one-stage and two-stage protocols already given, and the assumption that carcinogenic compounds affect each treated group. The expected number of animals required is highest for those sites with the power between 0.65 and 0.75 and decreases for tissues at which power is either higher or lower.
To illustrate more graphically the comparative performance of one-stage and two-stage procedures, we present examples based on simulated data. It was assumed that there was at most one active site, that the tumor incidence rate at one site does not affect the incidence rate at another site, and that carcinogenic compounds affect .each sex and species of test animal in a similar manner. In addition, it was assumed that an active compound leads to an additive increase of 0.10 for each sex-species group.
We considered a pool of 2,000 compounds as specified in table 12. The decision rules are those given in the previous sections. 
DISCUSSION
Carcinogenesis screens are large-scale testing programs whose purpose is identification of chemicals with carcinogenic potential. Such screens are no longer performed in isolated experiments. When designs are evaluated for use in these screens, it is important to specify carefully the desired operating characteristics for the screen, i.e., the probabilities of a false positive or false negative associated with the use of a screen as well as constraints in the utilization of resources and all the clinical, pathologic, and toxicologic parameters. Competing program designs can then be evaluated by a comparison of how soon these designs can be expected to reach decisions about compounds submitted for testing, subject to accuracy and validity concerns. In this work, we proposed animal carcinogenesis screens in which smaller numbers of animals at stage I are used than the current screening designs and that retest equivocal compounds.
For purposes of our development, we used as a comparison the present NCI one-stage protocol. From this investigation, two-stage screening designs that have sensitivity and specificity comparable to those of the current one-stage design clearly can be developed. In particular, the two-stage design has somewhat greater specificity and slightly less sensitivity than those of the current screen. The relative differences in power are largest for very weak carcinogens, but power is small for such compounds under either design. Even though the two-stage and one-stage designs have comparable specificity and sensitivity, the two-stage screen requires 12-28% fewer animals per compound tested. The benefits of a two-stage testing program are best seen in the context of a routine screening program. The example presented in the previous section indicates that a two-stage program can make decisions on about 30% more compounds per unit time than the current one-stage screen. This means that a two-stage screen allows more decisions per test period to be made concerning carcinogenicity with the use of the same resources. In addition, by allowing for replication when there is doubt, a two-stage design of the type considered here provides more information on equivocal compounds for which decision-making is currently the most difficult.
In addition, we have investigated the performance of a one-stage 35-animal-per-group screen using the decision rules developed in "Existing Program and a TwoStage Alternative." The false-positive rate is 0.03, which is lower than that for either of the screens considered before; however, the power of this screen is appreciably lower than that of any of the other screens presented.
Other points related to both the design and the evaluation of carcinogenicity screens and screening programs are worthy of further consideration. In particular, the decision rules we have developed for both the one-stage and two-stage screens are not unique. Other sample sizes, decision rules, or design parameters may well lead to screens and screening programs having more desirable operating characteristics. It is also interesting to consider a number of alternative methods for use in the definition of suspicious outcomes. These methods make more complete use of prior information about spontaneous tumor incidence rates and lead to alternative analyses for both the one-stage and twostage screens.
Throughout the evaluations performed in this paper, a simple model was used. Several extensions of this model are possible, including allowance for doseresponse eftects and allowance tor second-stage tests to concentrate on those sites and types of animals that were suspicious at stage I. Such modifications would increase the savings and the sensitivity possible in a two-stage screening program.
In this work we have demonstrated that a carcinogenesis screen based upon two-stage designs can have sensitivity and specificity comparable to those of onestage designs, yet require fewer animals per compound and lead to a substantial increase in the number of decisions made per unit time, with the use of the same resources as the present one-stage screen. We emphasize that to develop this two-stage design, the process of evaluating the results of carcinogenesis experiments was simplified. The assessment of this biologic process is not just a statistical problem inasmuch as substantial biologic evaluation is needed. The particular two-stage design proposed should, therefore, be regarded as a starting point for discussion. We welcome comments and suggestions from all interested scientists.
